Christopher Posner - 28 Nov 2022 Form 3 Insider Report for KEMPHARM, INC (ZVRA)

Role
Director
Signature
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Christopher A. Posner
Issuer symbol
ZVRA
Transactions as of
28 Nov 2022
Net transactions value
$0
Form type
3
Filing time
30 Nov 2022, 15:40:23 UTC
Previous filing
18 Nov 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZVRA Stock Option (right to buy) 28 Nov 2022 Common Stock 22,500 $4.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 33.33% of the total shares subject to the option vest in equal annual installments beginning on November 28, 2023 through November 28, 2025, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. The option expires ten years after the date of grant.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney.